Myriad Genetics, Inc. (MYGN) Given Average Rating of “Hold” by Brokerages
Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) have earned a consensus recommendation of “Hold” from the seventeen analysts that are covering the stock, MarketBeat reports. Five research analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have assigned a buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $22.25.
Several equities analysts have recently weighed in on MYGN shares. BidaskClub upgraded Myriad Genetics from a “hold” rating to a “buy” rating in a report on Saturday, June 17th. Cowen and Company reiterated a “market perform” rating and set a $19.00 price objective on shares of Myriad Genetics in a report on Tuesday, March 28th. Jefferies Group LLC reiterated a “hold” rating and set a $21.00 price objective (up previously from $18.00) on shares of Myriad Genetics in a report on Wednesday, May 3rd. Deutsche Bank AG lifted their price objective on Myriad Genetics from $15.00 to $20.00 and gave the company a “sell” rating in a report on Monday, May 8th. Finally, J P Morgan Chase & Co reiterated an “underweight” rating and set a $16.00 price objective on shares of Myriad Genetics in a report on Friday, June 30th.
Myriad Genetics (NASDAQ MYGN) opened at 24.32 on Friday. The firm has a market cap of $1.66 billion, a P/E ratio of 51.97 and a beta of 0.32. Myriad Genetics has a one year low of $15.15 and a one year high of $32.54. The stock has a 50 day moving average price of $24.27 and a 200-day moving average price of $20.02.
Myriad Genetics (NASDAQ:MYGN) last released its quarterly earnings data on Tuesday, May 2nd. The company reported $0.27 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.24 by $0.03. Myriad Genetics had a return on equity of 10.53% and a net margin of 4.26%. The business had revenue of $196.90 million for the quarter, compared to analysts’ expectations of $188.89 million. Analysts predict that Myriad Genetics will post $1.01 EPS for the current fiscal year.
Large investors have recently made changes to their positions in the stock. Ameritas Investment Partners Inc. bought a new position in Myriad Genetics during the first quarter valued at $112,000. Creative Planning raised its position in Myriad Genetics by 11.8% in the first quarter. Creative Planning now owns 6,371 shares of the company’s stock valued at $122,000 after buying an additional 671 shares during the period. State of Alaska Department of Revenue bought a new position in Myriad Genetics during the first quarter valued at $144,000. Karp Capital Management Corp bought a new position in Myriad Genetics during the first quarter valued at $223,000. Finally, Opus Point Partners Management LLC bought a new position in Myriad Genetics during the fourth quarter valued at $232,000.
Myriad Genetics Company Profile
Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.
Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.